Table 3.

Practice-level rates of lipid-lowering therapy use and its variation among patients with LDL-C ≥ 190 mg/dL

Medication Class	Practice-level rates of Use of a medication class Median (IQR)	MRR (95% CI) (unadjusted)	MRR (95% CI) (adjusted for patient characteristics)*	MRR (95% CI) (adjusted for patient and practice characteristics)†
Any statin	56% (47.3%–64.8%)	1.24 (1.21–1.27)	1.22 (1.19–1.24)	1.20 (1.17–1.23)
High-intensity statin therapy	30.2% (12.1%–41.1%)	2.51 (2.29–2.73)	2.34 (2.15–2.54)	2.31 (2.12–2.51)
Lipid lowering therapy associated with ≥50% LDL-C reduction	31.8% (15.3%–45.5%)	2.29 (2.11–2.47)	2.21 (2.04–2.38)	2.12 (1.95–2.28)
Ezetimibe therapy	5.8% (2.8%–9.8%)	2.56 (2.34–2.78)	2.42 (2.22–2.62)	2.42 (2.21–2.63)
PCSK9 inhibitors	0.16% (0–1.9%)	2.76 (2.37–3.14)	2.56 (2.12–2.79)	2.38 (2.04–2.72)

IQR = interquartile range, MRR= median rate ratio, CI = confidence interval, PCSK9 = proprotein convertase subtilisin/kexin

^*Adjusted for patient’s age, sex, insurance status [private vs. public, vs. others], history of hypertension, diabetes, current smoking, history of coronary artery disease, stroke, or peripheral artery disease

^†Adjusted for patient characteristics plus adjusted for practice-level characteristics (geographical location of the practice where patient is seeking care and the number of years that the practice is participating in the PINNACLE^® registry)